logo

For the Inventor, By the Inventor

Koenigstein, Germany

Jurgen K Sandow

This inventor holds 16 USPTO granted patents, plus 1 CIPO patent. Top assignee: Hoechst Aktiengesellschaft. Active years: 1977-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jurgen K Sandow. Retrieved from https://idiyas.com/inventor/jurgen-k-sandow

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 100.0


Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 328(Granted Patents)


Location History:

  • Frankfurt-am-Main, DE (1977)
  • Konigstein, Taunus, DE (1978)
  • Konigstein, DE (1981 - 1986)
  • Konigstein/Taunus, DE (1990 - 1995)
  • Glashutten/Taunus, DE (1996)
  • Glashutten, DE (1995 - 1997)

Company Filing History:

goldMedal16 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1977-1997

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 5661174 - Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their (1997-08-26),
2. 5565423 - Cyclopeptides and their use as absorption promoters when applied to the (1996-10-15),
3. 5498617 - Guanidinealkyl-1,1-bisphosphonic acid derivatives process for their (1996-03-12),
4. 5434138 - Gonadoliberin antagonists (1995-07-18),
5. 5395826 - Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their (1995-03-07),
6. 5091367 - Analogs of gonadoliberin with improved solubility, methods for their (1992-02-25),
7. 5091365 - Cyclic peptides as promoters of absorption on administration onto the (1992-02-25),
8. 5071836 - Competitive gonadoliberin antagonists (1991-12-10),
9. 4941874 - Device for the administration of implants (1990-07-17),
10. 4621073 - Cyclic peptides having somatostatin activity (1986-11-04),
11. 4395400 - Nonapeptide, a process for its preparation, an agent containing it and (1983-07-26),
12. 4377575 - Corticoid-17-(alkyl carbonates) and process for their manufacture (1983-03-22),
13. 4263282 - LH-RH-Peptides as contraceptives (1981-04-21),
14. 4118483 - Peptides having gonadoliberin activity and process for their manufacture (1978-10-03),
15. 4024248 - Peptides having LH-RH/FSH-RH activity (1977-05-17),

Title: Jurgen K Sandow: Innovator in Pharmaceutical Chemistry

Introduction

Jurgen K Sandow is a prominent inventor based in Königstein/Taunus, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 16 patents. His work focuses on developing innovative compounds that address critical health issues.

Latest Patents

Among his latest patents are the Guanidinealkyl-1,1-bisphosphonic acid derivatives, which are effective compounds for the treatment and prophylaxis of degenerative bone disorders. These compounds are utilized as pharmaceuticals, showcasing their importance in medical applications. Additionally, he has developed cyclopeptides that serve as absorption promoters when applied to the mucosa, further demonstrating his expertise in creating effective therapeutic agents.

Career Highlights

Jurgen K Sandow has had a distinguished career, primarily working with Hoechst Aktiengesellschaft, a leading company in the pharmaceutical industry. His innovative research and development efforts have led to advancements in drug formulation and delivery systems.

Collaborations

Throughout his career, Sandow has collaborated with notable colleagues, including Wolfgang König and Rolf Geiger. These partnerships have contributed to the success of his projects and the advancement of pharmaceutical science.

Conclusion

Jurgen K Sandow's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to impact the development of effective treatments for various health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…